REGULATION OF NEURODATA MARKETPLACE PROHIBITION LAW

1. INTRODUCTION

Neurodata Marketplace Prohibition Law concerns the legal restriction or prohibition of commercial transactions involving personal brain-related information, neural signals, cognitive patterns and neurological data without legitimate legal authority and adequate safeguards.

Neurodata may be collected through electroencephalography (EEG), brain-computer interfaces, neuroimaging devices, neural implants and wearable neurotechnology. Such information may reveal an individual's mental states, emotional responses, cognitive characteristics, neurological conditions and behavioural patterns.

Commercialisation of neurodata creates serious risks involving mental privacy, psychological manipulation, discrimination, unauthorised profiling, identity theft and exploitation of vulnerable individuals.

The principal objective of this developing legal framework is to prevent the unrestricted buying, selling, licensing and commercial exploitation of identifiable neurodata while permitting legitimate medical treatment and appropriately supervised scientific research.

2. INTERNATIONAL LEGAL AND REGULATORY FRAMEWORK

A. OECD RECOMMENDATION ON RESPONSIBLE INNOVATION IN NEUROTECHNOLOGY, 2019

The OECD Recommendation establishes principles for responsible neurotechnology development. Principle 7 requires safeguards for personal brain data, informed consent, confidentiality, individual control and protection against commercial discrimination.

B. UNESCO UNIVERSAL DECLARATION ON BIOETHICS AND HUMAN RIGHTS, 2005

The Declaration establishes principles of human dignity, autonomy, informed consent, privacy and confidentiality. These principles are relevant to preventing exploitative neurodata transactions.

C. GLOBAL PRIVACY ASSEMBLY RESOLUTION ON NEUROTECHNOLOGIES, 2024

The resolution recognises neurodata as highly sensitive information and advocates stronger protections, restrictions on harmful processing, transparency and privacy-by-design safeguards.

These international instruments provide important governance standards, although they do not themselves establish a universal prohibition on every neurodata marketplace.

3. INDIAN LEGAL FRAMEWORK

India does not currently have a standalone statute specifically prohibiting all commercial neurodata marketplaces. However, several existing legal provisions are relevant.

A. CONSTITUTION OF INDIA

Article 21 protects privacy, dignity, personal liberty and individual autonomy. Commercial exploitation of intimate neurological information without a valid legal basis may raise constitutional concerns.

B. DIGITAL PERSONAL DATA PROTECTION ACT, 2023

The Act establishes requirements concerning lawful processing, consent, individual rights, data security and accountability. Identifiable neurodata may fall within its definition of digital personal data.

Importantly, the substantive processing provisions are scheduled to commence eighteen months after the November 2025 commencement notification, namely May 2027. Therefore, their commencement must be distinguished from the provisions already in force.

C. INFORMATION TECHNOLOGY ACT, 2000

Section 43A and the applicable Sensitive Personal Data or Information Rules, 2011 provide relevant protections concerning specified sensitive information, including physical, physiological and mental health conditions and biometric information.

D. CONSUMER PROTECTION ACT, 2019

Misleading commercial representations, unfair trade practices and deficient services involving neurodata may attract consumer protection remedies.

4. PROHIBITED AND RESTRICTED COMMERCIAL ACTIVITIES

An effective prohibition framework should address:

Unauthorised sale of identifiable neural recordings to advertisers or commercial data brokers.

Trading in cognitive profiles without a valid legal basis.

Commercial exploitation of children's neurodata without appropriate legal safeguards.

Selling neurological information to employers or insurers for discriminatory profiling.

Unauthorised transfer of neural information to third-party platforms.

Manipulative commercial targeting based on inferred emotions, vulnerabilities or cognitive conditions.

Legitimate medical treatment, properly authorised research and carefully regulated public-interest activities should be distinguished from exploitative commercial trading.

5. IMPORTANT CASE LAWS

The following judgments provide relevant judicial principles. They are analogous authorities rather than decisions directly adjudicating a neurodata marketplace prohibition statute.

1. Justice K.S. Puttaswamy v. Union of India (2017) – DIRECT ANALOGOUS AUTHORITY

The Supreme Court recognised privacy as a fundamental right under Article 21 and Part III of the Constitution. Its principles support protection against unauthorised commercial exploitation of intimate neural information.

2. Selvi v. State of Karnataka (2010) – DIRECT ANALOGOUS AUTHORITY

The Supreme Court held involuntary administration of narcoanalysis, polygraph and Brain Electrical Activation Profile tests unconstitutional in the circumstances examined. The judgment is particularly relevant to mental privacy, cognitive autonomy and protection against compelled extraction of brain-related information.

3. District Registrar and Collector v. Canara Bank (2005) – ANALOGOUS AUTHORITY

The Supreme Court considered privacy and protection against unjustified intrusion into private records. Its reasoning is relevant to unauthorised access to confidential neurological databases.

4. R. Rajagopal v. State of Tamil Nadu (1994) – ANALOGOUS AUTHORITY

The Supreme Court recognised privacy protections concerning personal information and private affairs. These principles are relevant to unauthorised publication and commercial disclosure of personal neurodata.

5. Mr. X v. Hospital Z (1998) – ANALOGOUS AUTHORITY

The Supreme Court considered medical confidentiality and circumstances in which disclosure of confidential medical information may be justified. The judgment is relevant to controlling the disclosure of sensitive neurological and clinical information.

6. K.S. Puttaswamy (Aadhaar) v. Union of India (2018) – DIRECT ANALOGOUS AUTHORITY

The Supreme Court examined proportionality, privacy and informational safeguards in the context of identity-related data processing. Its reasoning is relevant to determining whether commercial neurodata collection and sharing satisfy constitutional requirements.

6. LIABILITY AND ENFORCEMENT MECHANISMS

An effective regulatory framework should establish:

Civil liability for unlawful disclosure and commercial exploitation.

Appropriate penalties for unauthorised processing and data breaches.

Regulatory investigation of neurodata brokerage businesses.

Mandatory security audits and transparent data-sharing agreements.

Rights to access, correction and deletion where provided by applicable law.

Restrictions on discriminatory employment and insurance practices.

Independent ethical review of neurological research involving human participants.

Liability should extend, where legally established, to data brokers, technology developers, healthcare institutions and organisations responsible for unlawful processing.

7. CONCLUSION

Neurodata Marketplace Prohibition Law represents an emerging area of privacy, constitutional and technology regulation. Its central purpose is to prevent the unrestricted commercial exploitation of information capable of revealing an individual's neurological and cognitive characteristics.

India's constitutional privacy jurisprudence, information technology legislation and developing digital personal data protection framework provide an important foundation for this regulation. A comprehensive framework should distinguish legitimate medical and scientific uses from exploitative commercial transactions and establish enforceable standards for consent, confidentiality, accountability and compensation.

Ultimately, neurological information should be governed as an important dimension of personal autonomy and human dignity, rather than treated as an unrestricted commercial commodity.